Results 81 to 90 of about 14,520 (202)

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma

World Journal of Surgical Oncology, 2008
Background The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
Rampaul Rajendra Singh, Tang Jasmine YM, Cheung Kwok L   +2 more
doaj   +1 more source

Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Ini

, 2015
BACKGROUND: The median survival for women with hormone-receptor-positive (HR+) stage IV metastatic breast cancer (MBC) is 36 months. Strategies to improve outcome for postmenopausal women, include combinations of aromatase inhibitors (AIs) with either ...
Gralow, Julie, Daniel Hayes, Lew, Danika, Hayes, Daniel, Tripathy, Debu, Peter Kuhn, Julie Gralow, Moore, Halle, Debu Tripathy, Halle Moore, Kuhn, Peter, Hicks, James, Danika Lew, Schott, Anne, George Somlo, William Barlow, Gabriel Hortobagyl, James Hicks, Barlow, William, Hortobagyl, Gabriel, Somlo, George, Anne Schott   +21 more
core   +1 more source

Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer

Journal of Nanobiotechnology
Background Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormone receptor-positive breast cancer.
Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang, Yin Guo-Bing   +7 more
doaj   +1 more source

Adding capivasertib to fulvestrant in patients with hormone receptor-positive advanced breast cancer: a cost-effectiveness analysis

Frontiers in Pharmacology
ObjectiveCapivasertib, a novel pan-AKT inhibitor, shows significant antitumor activity against hormone receptor-positive advanced breast cancer. However, its cost-effectiveness of this treatment remains uncertain.
Yitian Lang, Qingqing Chai, Yan Lin, Bin Wu, Xiaoyan Liu   +4 more
doaj   +1 more source

Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV‐471

Cancer Innovation, Volume 5, Issue 3, June 2026.
Yu Rao
wiley   +1 more source

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Case Reports in Oncology, 2010
We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies.
H. Hawle, D. Hess, A. Mueller, B. Thuerlimann   +3 more
doaj   +1 more source

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

Signal Transduction and Targeted Therapy
CDK2 is a principal mediator of CDK4/6 resistance. Concurrent CDK2/4/6 blockade may be effective in treating HR-positive, HER2-negative advanced breast cancer (ABC).
Yongmei Yin, Qingyuan Zhang, Tao Sun, Chunfang Hao, Zhihong Wang, Jin Yang, Yongsheng Wang, Yanxia Shi, Jing Sun, Quchang Ouyang, Haichuan Su, Jinsheng Wu, Lu Gan, Meng Han, Liming Gao, Xiaojia Wang, Bing Zhao, Hui Li, Jiuda Zhao, Hongwei Yang, Fangling Ning, Fuguo Tian, Juliang Zhang, Hongmei Sun, Zhaofeng Niu, Hong Zong, Aimin Zang, Xinshuai Wang, Xinyu Qian, Shikai Wu, Jianyun Nie, Lijia He, Ying Cheng, Yanrong Hao, Yi Zhai, Huiping Li, Jingfen Wang, Shihong Wei, Man Li, Yunjiang Liu, Hongqiang Guo, Qun Hu, Lina Liu, Xinghua Han, Ruizhen Luo, Mingli Ni, Xianjun Tang, Zhenhua Zhai, Meiqian Ding, Haibo Wang, Peng Shen, Xian Wang, Lian Liu, Wenyan Chen, Gang Liu, Zhengwen Cai, Zefei Jiang   +56 more
doaj   +1 more source

Fulvestrant in the treatment of luminal metastatic breast cancer: The balance of effectiveness and safety

, 2021
The review presents the results of studies of fulvestrant in metastatic breast cancer (MBC). Hormone therapy is an effective method of treating hormone-positive metastatic breast cancer even in the presence of visceral metastases in the absence of a ...
Koroleva I.A.
core  

Fulvestrant [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Unfolding the role of stress response signaling in endocrine resistant breast cancers

Frontiers in Oncology, 2015
The unfolded protein response (UPR) is an ancient stress response that enables a cell to manage the energetic stress that accompanies protein folding.
Robert eClarke, Katherine L Cook
doaj   +1 more source